Literature DB >> 17367700

Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.

Veena K Ranganath1, Daniel E Furst.   

Abstract

During the 10-year period since the last review was done by Gardner and Furst, studies have furthered the knowledge of the use of disease-modifying antirheumatic drugs (DMARDs) in the elderly rheumatoid arthritis (RA) patient. This article briefly reviews the clinical pharmacology of humans as they age, and details the effects of aging on the specific pharmacokinetics and responses to commonly used DMARDs. There has been some progress in understanding the elderly RA patient; however, data are insufficient to provide much confidence in DMARDs effects in the elderly.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17367700     DOI： 10.1016/j.rdc.2006.12.011

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  9 in total

1.  Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).

Authors:  Sara A Colopy; Theresa A Baker; Peter Muir
Journal:  J Am Vet Med Assoc       Date:  2010-02-01       Impact factor: 1.936

Review 2.  Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.

Authors:  Alla Ishchenko; Rik J Lories
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

3.  Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing Patients.

Authors:  Marta Novella-Navarro; Alejandro Balsa
Journal:  Drugs Aging       Date:  2022-09-15       Impact factor: 4.271

Review 4.  Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.

Authors:  Alejandro Díaz-Borjón
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 5.  Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors.

Authors:  Blas Y Betancourt; Ann Biehl; James D Katz; Ananta Subedi
Journal:  Rheum Dis Clin North Am       Date:  2018-06-12       Impact factor: 2.670

6.  Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment.

Authors:  Stefano Alivernini; Daniela Mazzotta; Angelo Zoli; Gianfranco Ferraccioli
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 7.  Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management.

Authors:  Francesco Caso; Marco Tasso; Maria Sole Chimenti; Luca Navarini; Carlo Perricone; Nicolò Girolimetto; Rosario Peluso; Antonio Del Puente; Antonella Afeltra; Roberto Perricone; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

8.  Alopecia areata: a new treatment plan.

Authors:  Adel Alsantali
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-07-22

9.  Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register.

Authors:  Paloma Vela; Carlos Sanchez-Piedra; Carolina Perez-Garcia; María C Castro-Villegas; Mercedes Freire; Lourdes Mateo; Cesar Díaz-Torné; Cristina Bohorquez; Juan M Blanco-Madrigal; Inmaculada Ros-Vilamajo; Silvia Gómez; Rocio Caño; Fernando Sánchez-Alonso; Federico Díaz-González; Juan J Gómez-Reino
Journal:  Arthritis Res Ther       Date:  2020-06-15       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.